Lonza Makes Strategic Acquisition at Modest Valuation — Market Talk

What happened

Lonza Group agreed to buy the U.S. contract-drug-manufacturing network from Germany's Merck. Lonza said the deal was based on a valuation, including debt, in the low- to mid-triple-digit Swiss-franc range, which Stifel interprets as between 300 million and 400 million francs.

Confirmed

Global impact / market context

The price looks low compared with the roughly $780 million Merck paid for Exelead alone in 2022, suggesting a valuation reset. For Lonza, returns depend on how much of the network's capacity it uses and how much extra investment it must make.

Analyst inference

Stifel calls the valuation attractive for Lonza, implying the company is buying capacity cheaply to expand in the U.S. The analyst also flags that actual returns hinge on plant utilization, meaning how full the factories run, and on added spending, so the benefit is not guaranteed.

Analyst inference

What to watch

1. Lonza said the deal's valuation, including debt, sits in the low- to mid-triple-digit Swiss-franc range, so watch for the final price confirmation and any disclosed deal terms. Confirmed
2. Watch for Lonza's plans to invest more in the U.S. network and lift its use of the plants, since Stifel says returns depend on utilization and incremental investment. Proposed
3. Watch whether other drugmakers sell similar contract-manufacturing sites at low prices, which would confirm a weaker market for these assets and pressure valuations across the industry. Analyst inference

Evidence

• Original source link unavailable